The increasing prevalence of dyslexia is anticipated to fuel the growth of the global dyslexia treatment market at a CAGR of 7.1% during the forecast period of 2023 to 2032.

Market Research Future (MRFR) has published a cooked research report on the “Global Dyslexia Treatment Market” that contains information from 2018 to 2032. The Dyslexia Treatment market is estimated to register a CAGR of 7.1% during the forecast period of 2023 to 2032.

Market Highlights

The global Dyslexia Treatment market is accounted to register a CAGR of 7.1% during the forecast period and is estimated to reach USD 48.8 Billion by 2032.

The dyslexia treatment market refers to the industry that encompasses products and services aimed at diagnosing, managing, and improving the symptoms of dyslexia, a learning disorder characterized by difficulties in reading, writing, and spelling. This market includes interventions such as educational therapies, assistive technologies, specialized tutoring, and cognitive training programs tailored to address the specific needs of individuals with dyslexia.

Key Players:

MRFR recognizes the following companies as the key players in the global Dyslexia Treatment market— Pfizer, Inc. (US), Speechify Inc. (US), Jubilant Pharma Limited (Singapore), Lingit AS (Norway), Soli (UK), Novartis AG (Switzerland), Lyfta (UK), GlaxoSmithKline (UK), Teva Pharmaceutical Industries Ltd (Israel), Eli Lilly & Company (US), RPG Life Sciences Ltd (India), Hopalai D.O.O. (Slovenia).

Segment Analysis

The global Dyslexia Treatment market has been segmented based on Type, Treatment & Diagnosis and End User.

On the basis of Type, the market is segmented into phonological dyslexia, surface dyslexia, and others. In terms of the revenue generated by the dyslexia treatment market in 2022, the phonological dyslexia type segment held the most share. This is usually due to developmental (genetic/inherited) factors, though it can occasionally be acquired due to a stroke or Alzheimer's disease.

Based on Treatment & Diagnosis, the global Dyslexia Treatment market has been segmented into treatment & diagnosis, includes treatment, and diagnosis. Medication and tool are other subcategories of the therapy sector. In terms of revenue generated by dyslexia treatments, the therapy segment led the market in 2022.

Based on End User, the global Dyslexia Treatment market has been segmented into specialty center, home care, hospitals & clinics, and others. In terms of the revenue generated by the dyslexia treatment market in 2022, the speciality centre held the greatest market share. Due to the fact that children with dyslexia typically also have another psychiatric problem, speciality centres have become more popular in dyslexia situations.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Dyslexia Treatment Market Research Report

Regional Analysis

The global Dyslexia Treatment market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Dyslexia Treatment market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Dyslexia Treatment market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Dyslexia Treatment market comprises of Middle East, Africa, and Latin America.

The North America Dyslexia Treatment Market dominated this market in 2022. The existence of significant key companies headquarters in the region, like Jubilant Cadista (US) and Speechify (US), favourable government regulations, the high prevalence of dyslexia, and the developed healthcare infrastructure are all factors contributing to this.

Additionally, the second-largest market share for Dyslexia Treatment is held by Europe. Other factors boosting the market in Europe include the rising frequency of dyslexia, quick technical improvements, and shorter treatment times.

Moreover, the market for dyslexia treatments in Asia-Pacific is anticipated to expand significantly over the course of the projected period. This is brought on by the proliferation of market participants and rising disposable income. Additionally, the Asia-Pacific region's dyslexia treatment market in India grew at the fastest rate, while the market in China had the biggest market share. Asia-Pacific is therefore expected to experience the fastest increase over the projection period.

Key Findings of the Study

• The North America Dyslexia Treatment Market dominated this market in 2022.


• Based on Treatment & Diagnosis, the treatment segment dominated the market in 2022 with respect to the dyslexia treatment market revenue. 


• Pfizer, Inc. (US), Speechify Inc. (US), Jubilant Pharma Limited (Singapore), Lingit AS (Norway), Soli (UK), Novartis AG (Switzerland), Lyfta (UK), GlaxoSmithKline (UK), Teva Pharmaceutical Industries Ltd (Israel), Eli Lilly & Company (US), RPG Life Sciences Ltd (India), Hopalai D.O.O. (Slovenia).